4974-58-7

Basic information

• Product Name: 4-Biphenylylglyoxal
• Synonyms: 4-Biphenylylglyoxal;alpha-Oxo-(1,1'-biphenyl)-4-acetaldehyde;2-keto-2-(4-phenylphenyl)acetaldehyde;2-oxo-2-(4-phenylphenyl)acetaldehyde;2-oxo-2-(4-phenylphenyl)ethanal;2-([1,1'-Biphenyl]-4-yl)-2-oxoacetaldehyde;[1,1'-Biphenyl]-4-acetaldehyde, α-oxo-;4-BIPHENYLGLYOXAL(WXG02552)
• CAS NO: 4974-58-7
• Molecular Formula: C₁₄H₁₀O₂
• Molecular Weight: 210.228
• Mol File: 4974-58-7.mol
• Article Data: 17

Chemical Properties

• Boiling Point: 350.2°Cat760mmHg
• Flash Point: 144.1°C
• Appearance: /
• Density: 1.145g/cm³
• CAS DataBase Reference: 4-Biphenylylglyoxal(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Biphenylylglyoxal(4974-58-7)
• EPA Substance Registry System: 4-Biphenylylglyoxal(4974-58-7)

Safety Data

• Hazardous Substances Data: 4974-58-7(Hazardous Substances Data)

Usage

General Description

4-Biphenylylglyoxal is a chemical compound with the molecular formula C12H8O2. It is a derivative of biphenyl and glyoxal and is used in organic synthesis as a reactant and intermediate in the production of various compounds. It has potential applications in pharmaceuticals, agrochemicals, and materials science due to its unique structure and reactivity. 4-Biphenylylglyoxal has been studied for its potential use in the development of new drugs and materials with specific properties, and its synthesis and properties continue to be the subject of research in the field of organic chemistry.

Upstream product

• 40240-62-8 1-(2-([1,1'-biphenyl]-4-yl)-2-oxoethyl)pyridin-1-ium bromide 
• 135-73-9 2-Bromo-4'-phenylacetophenone 
• 33707-82-3 1-biphenyl-4-yl-2-piperidin-1-yl-ethanone 
• 92-91-1 biphenyl-4-acetaldehyde 

Downstream Products

• 1174-11-4 p-[(α-Ethoxy-p-phenylphenacyl)amino]benzoic acid 
• 94578-45-7 1-biphenyl-4-yl-2-phenylimino-ethanone 
• 17286-67-8 2-([1,1′-biphenyl]-4-yl)quinoxaline 
• 140472-99-7 Biphenyl-4-yl-(2-phenyl-1,9b-dihydro-5-oxa-3,3a-diaza-cyclopenta[a]naphthalen-4-yl)-methanone 
• 24342-51-6 1-Biphenyl-4-yl-2-(diethyl-hydrazono)-ethanone 
• 170157-97-8 6-(4-biphenyl)lumazine 
• 170157-98-9 7-(4-biphenyl)lumazine 
• 170158-18-6 7-(4-biphenyl)-1-(2-deoxy-5-O-dimethoxytrityl-β-D-ribofuranosyl)lumazine 
• 170158-21-1 6-(4-biphenyl)-1-(5-O-dimethoxytrityl-2-deoxy-α-D-ribofuranosyl)lumazine 
• 170158-17-5 6-(4-biphenyl)-1-(2-deoxy-5-O-dimethoxytrityl-β-D-ribofuranosyl)lumazine 
• 170158-02-8 7-(4-biphenyl)-1-(2-deoxy-3,5-di-O-p-toluoyl-β-D-ribofuranosyl)lumazine 
• 170158-06-2 7-(4-biphenyl)-1-(2-deoxy-3,5-di-O-p-toluoyl-α-D-ribofuranosyl)lumazine 
• 170158-14-2 7-(4-biphenyl)-1-(2-deoxy-α-D-ribofuranosyl)lumazine 

Relevant articles and documents

Ynonylation of Acyl Radicals by Electroinduced Homolysis of 4-Acyl-1,4-dihydropyridines

Herein we report the conversion of 4-Acyl-1,4-dihydropyridines (DHPs) into ynones under electrochemical conditions. The reaction proceeds via the homolysis of acyl-DHP under electron activation. The resulting acyl radicals react with hypervalent iodine(III) reagents to form the target ynones or ynamides in acceptable yields. This mild reaction condition allows wider functionality tolerance that includes halides, carboxylates, or alkenes. The synthetic utility of this methodology is further demonstrated by the late-stage modification of complex molecules.

Mono- or di-substituted imidazole derivatives for inhibition of acetylcholine and butyrylcholine esterases

Mono- or di-substituted imidazole derivatives were synthesized using a one-pot, two-step strategy. All imidazole derivatives were tested for AChE and BChE inhibition and showed nanomolar activity similar to that of the test compound donepezil and higher than that of tacrine. Structure activity relationship studies, docking studies to on X-ray crystal structure of AChE with PDB code 1B41, and adsorption, distribution, metabolism, and excretion (ADME) predictions were performed. The synthesized core skeleton was bound to important regions of the active site of AChE such as the peripheral anionic site (PAS), oxyanion hole (OH), and anionic subsite (AS). Selectivity of the reported test compounds was calculated and enzyme kinetic studies revealed that they behave as competitive inhibitors, while two of the test compounds showed noncompetitive inhibitory behavior. ADME predictions revealed that the synthesized molecules might pass through the blood brain barrier and intestinal epithelial barrier and circulate freely in the blood stream without binding to human serum albumin. While the toxicity of one compound on the WS1 (skin fibroblast) cell line was 1790 μM, its toxicity on the SH-SY5Y (neuroblastoma) cell line was 950 μM.

Synthesis of novel imidazopyridines and their biological evaluation as potent anticancer agents: A promising candidate for glioblastoma

Novel imidazopyridine derivatives were synthesized according to a very simple protocol and then subjected to cytotoxicity testing against LN-405 cells. Two of the compounds exhibited antiproliferative effects on LN-405 cells at 10 and 75 μM and were selected as lead compounds for further study. Safety experiment for lead compounds on WS1 was carried out and IC50 values were calculated as 480 and 844 μM. LN-405 cell line were incubated with the lead compounds and then tested for DNA damage by comet assay and effects on cell cycle using flow cytometry. The results of these two tests showed that both lead compounds affected the G0/G1 phase and did not allow the cells to reach the synthesis phase. The log BB (blood–brain barrier) and Caco-2 permeability of the synthesized molecules were calculated and it was shown that imidazopyridine derivatives taken orally are likely to pass through gastrointestinal membrane and the blood–brain barrier.